Kras and tumor immunity: friend or foe?
Open accessAbstract
With the recent breakthroughs in immunotherapy as curative treatments in certain tumor types, there has been renewed interest in the relationship between immunity and tumor growth.Although we are gaining a greater understanding of the complex interplay of immune modulating components in the tumor microenvironment, the specific role that tumor cells play in shaping the immune milieu is still not well characterized.In this review, we focus on how mutant Kras tumor cells contribute to tumor immunity, with a specific focus on processes induced directly or indirectly by the oncogene. KRAS' IMMUNOLOGISTICSThe discovery that oncogenic Kras could induce nuclear factor (NF)-κB activation in fibroblasts and epithelial cells provided the first direct evidence of its capacity to drive proinflammatory signaling in transformed cells (Finco et al. 1997;
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
KRAS mutant cancers are immunosuppressive because oncogenic K-Ras signaling induces expression of immune modulatory factors such as interleukin-10 and transforming growth factor β, promoting an immunosuppressive tumor microenvironment.
“KRAS mutant cancers are immunosuppressive in nature because oncogenic K-Ras signaling induces the expression of immune modulatory factors, such as interleukin-10 and transforming growth factor β to promote an immunosuppressive tumor microenvironment.93”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · see citing works
Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985 · see citing works
The Biology of Chemokines and their Receptors
Rossi, D., & Zlotnik, A. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.217 · Cited by 2,410 · see citing works
TRANSFORMING GROWTH FACTOR-β REGULATION OF IMMUNE RESPONSES
Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A.-K. L., & Flavell, R. A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090737 · Cited by 2,199 · see citing works
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · see citing works
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · see citing works
Pancreatitis and the Risk of Pancreatic Cancer
Lowenfels, A. B., Maisonneuve, P., Cavallini, G., Ammann, R., Lankisch, P. G., Andersen, J. R., DiMagno, E. P., Andrén‐Sandberg, Å., & Domellöf, L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305203282001 · Cited by 1,753 · see citing works
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,340 · see citing works
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324 · see citing works
Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00986-1 · Cited by 1,222 · cited 1× · see citing works
“Following up on these promising results, the CCR2 inhibitor PF-04136309 in combination with the chemotherapeutic regimen FOLFIRINOX is currently in clinical trials, with phase 1b results revealing 52% partial response and 47.8% of patients showing stable disease (Wang-Gillam et al. 2016).”
BackgroundInfluentialThe Molecular Biology of Leukocyte Chemoattractant Receptors
Murphy, P. M. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.003113 · Cited by 1,197 · see citing works
Is NF-κB a good target for cancer therapy? Hopes and pitfalls
Baud, V., & Karin, M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2781 · Cited by 1,059 · see citing works
Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959 · see citing works
Jess, T., Rungoe, C., & Peyrin–Biroulet, L. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.01.010 · Cited by 958 · see citing works
Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947 · cited 1× · see citing works
“Importantly, GM-CSF production by KrasG12D-expressing pancreatic tumor cells promoted the recruitment of MDSCs to the tumor microenvironment, which in turn fostered tumor growth by suppressing immune clearance by CD8+ T cells (Bayne et al. 2012; PylayevaGupta et al. 2012).”
BackgroundMitchem, J. B., Brennan, D. J., Knolhoff, B. L., Belt, B. A., Zhu, Y., Sanford, D. E., Belaygorod, L., Carpenter, D. H., Collins, L. I., Piwnica-Worms, D. R., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2731 · Cited by 943 · see citing works
Role of tumor-associated macrophages in tumor progression and invasion
Mantovani, A., Schioppa, T., Porta, C., Allavena, P., & Sica, A. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9001-7 · Cited by 885 · see citing works
Lesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.009 · Cited by 862 · see citing works
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis
Sparmann, A., & Bar‐Sagi, D. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.028 · Cited by 854 · see citing works
Self-citationImmune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki–Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 853 · see citing works
Steele, C. W., Karim, S. A., Leach, J. D. G., Bailey, P. J., Upstill‐Goddard, R., Rishi, L., Foth, M., Bryson, S., McDaid, K., Wilson, Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.014 · Cited by 850 · see citing works
Chemokine:Receptor Structure, Interactions, and Antagonism
Allen, S. J., Crown, S. E., & Handel, T. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090529 · Cited by 842 · see citing works
Transforming growth factor-β in T-cell biology
Gorelik, L., & Flavell, R. A. (2002) · Nature Reviews Immunology · doi:10.1038/nri704 · Cited by 792 · see citing works
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721 · see citing works
Self-citationCOPD prevalence is increased in lung cancer, independent of age, sex and smoking history
Young, R. P., Hopkins, R. J., CHRISTMAS, T. I., Black, P., Metcalf, P. A., & Gamble, G. D. (2009) · European Respiratory Journal · doi:10.1183/09031936.00144208 · Cited by 696 · see citing works
The pancreatic stellate cell: a star on the rise in pancreatic diseases
Omary, M. B., Lugea, A., Lowe, A. W., & Pandol, S. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30082 · Cited by 693 · see citing works
Mechanisms of Immune Evasion by Tumors
Drake, C. G., Jaffee, E. M., & Pardoll, D. M. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 690 · see citing works
Origins of tumor-associated macrophages and neutrophils
Cortez‐Retamozo, V., Etzrodt, M., Newton, A., Rauch, P. J., Chudnovskiy, A., Berger, C., Ryan, R. J. H., Iwamoto, Y., Marinelli, B. S., Gorbatov, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113744109 · Cited by 680 · see citing works
The transcriptional landscape and mutational profile of lung adenocarcinomaPreprint
Seo, J., Ju, Y. S., Lee, W., Shin, J.-Y., Lee, J. J.-K., Bleazard, T., Lee, J., Jung, Y. J., Kim, J. O., Shin, J.-Y., et al. (2012) · Genome Research · doi:10.1101/gr.145144.112 · Cited by 589 · see citing works
Ene–Obong, A., Clear, A. J., Watt, J., Wang, J., Fatah, R., Riches, J. C., Marshall, J. F., Chin–Aleong, J., Chelala, C., Gribben, J. G., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.025 · Cited by 579 · see citing works
Significance of M2-Polarized Tumor-Associated Macrophage in Pancreatic Cancer
Kurahara, H., Shinchi, H., Mataki, Y., Maemura, K., Noma, H., Kubo, F., Sakoda, M., Ueno, S., Natsugoe, S., & Takao, S. (2009) · Journal of Surgical Research · doi:10.1016/j.jss.2009.05.026 · Cited by 552 · see citing works
Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells
Gabrilovich, D. I., Velders, M. P., Sotomayor, E. M., & Kast, W. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5398 · Cited by 538 · see citing works
Mace, T. A., Shakya, R., Pitarresi, J. R., Swanson, B. J., McQuinn, C. W., Loftus, S. N., Nordquist, E., Cruz‐Monserrate, Z., Yu, L., Young, G. S., et al. (2016) · Gut · doi:10.1136/gutjnl-2016-311585 · Cited by 535 · see citing works
Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression
Fukuda, A., Wang, S. C., Morris, J. P., Folias, A. E., Liou, A., Kim, G. E., Akira, S., Boucher, K., Firpo, M., Mulvihill, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.002 · Cited by 531 · see citing works
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W. P., Lim, E. L., Bouabe, H., Scudamore, C. L., Hancox, T. C., Maecker, H. L., et al. (2014) · Nature · doi:10.1038/nature13444 · Cited by 530 · see citing works
Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer
Bailey, J. M., Swanson, B. J., Hamada, T., Eggers, J. P., Singh, P. K., Caffrey, T. C., Ouellette, M. M., & Hollingsworth, M. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0291 · Cited by 520 · see citing works
Guerra, C., Collado, M., Navas, C., Schuhmacher, A. J., Hernández-Porras, I., Cañamero, M., Rodriguez-Justo, M., Serrano, M., & Barbacid, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.011 · Cited by 516 · see citing works
Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Gunderson, A. J., Kaneda, M. M., Tsujikawa, T., Nguyen, A. V., Affara, N. I., Ruffell, B., Gorjestani, S., Liudahl, S. M., Truitt, M., Olson, P., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0827 · Cited by 485 · see citing works
Risk of pancreatic adenocarcinoma in chronic pancreatitis
Malka, D., Hammel, P. R., Maire, F., Rufat, P., Madeira, I., Pessione, F., Lévy, P., & Ruszniewski, P. B. (2002) · Gut · doi:10.1136/gut.51.6.849 · Cited by 456 · see citing works
Characterization of two high affinity human interleukin-8 receptors.
Lee, J., Horuk, R., Rice, G. C., Bennett, G. L., Camerato, T. R., & Wood, W. I. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41997-7 · Cited by 425 · see citing works
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis
Ancrile, B., Lim, K.-H., & Counter, C. M. (2007) · Genes & Development · doi:10.1101/gad.1549407 · Cited by 422 · see citing works
Mace, T. A., Ameen, Z., Collins, A., Wojcik, S. E., Mair, M., Young, G. S., Fuchs, J. R., Eubank, T. D., Frankel, W. L., Bekaii‐Saab, T., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4601 · Cited by 413 · see citing works
McAllister, F., Bailey, J. M., Alsina, J., Nirschl, C. J., Sharma, R., Fan, H., Rattigan, Y., Roeser, J. C., Lankapalli, R. H., Zhang, H., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.014 · Cited by 405 · see citing works
Inhibition of Ras for Cancer Treatment: The Search Continues
Baines, A. T., Xu, D., & Der, C. J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.121 · Cited by 385 · see citing works
Finco, T. S., Westwick, J. K., Norris, J. L., Beg, A. A., Der, C. J., & Baldwin, A. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24113 · Cited by 375 · see citing works
Nemunaitis, J. J., Dillman, R. O., Schwarzenberger, P. O., Senzer, N. N., Cunningham, C. C., Cutler, J., Tong, A., Kumar, P., Pappen, B. O., Hamilton, C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5335 · Cited by 365 · see citing works
Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis
Xue, J., Sharma, V., Hsieh, M. H., Chawla, A., Murali, R., Pandol, S. J., & Habtezion, A. (2015) · Nature Communications · doi:10.1038/ncomms8158 · Cited by 363 · see citing works
IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia
Pylayeva‐Gupta, Y., Das, S., Handler, J. S., Hajdu, C. H., Coffre, M., Koralov, S. B., & Bar‐Sagi, D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0843 · Cited by 357 · see citing works
Self-citationLöhr, M., Klöppel, G., Maisonneuve, P., Lowenfels, A. B., & Lüttges, J. (2005) · Neoplasia · doi:10.1593/neo.04445 · Cited by 343 · cited 1× · see citing works
“The significance of mutant Kras’ cooperation with additional inflammatory diseases in tumorigenesis is emphasized by the observation that oncogenic mutations in Kras have been de- tected in disease-free pancreas of healthy individuals (Terhune et al. 1998; Lüttges et al. 1999; Löhr et al. 2005).”
Backgroundγδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation
Daley, D., Zambirinis, C. P., Seifert, L., Akkad, N., Mohan, N., Werba, G., Barilla, R., Torres-Hernandez, A., Hundeyin, M., Mani, V. R. K., et al. (2016) · Cell · doi:10.1016/j.cell.2016.07.046 · Cited by 329 · see citing works
Self-citationT helper 17 cells play a critical pathogenic role in lung cancer
Chang, S. H., Mirabolfathinejad, S. G., Katta, H., Cumpian, A. M., Gong, L., Caetano, M. S., Moghaddam, S. J., & Dong, C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319051111 · Cited by 326 · see citing works
Löhr, M. J., Schmidt, C., Ringel, J., Kluth, M., Müller, P., Nizze, H., & Jesnowski, R. (2001) · PubMed · Cited by 323 · see citing works
Pancreatic stellate cells: a starring role in normal and diseased pancreas
Apte, M. V., Pirola, R. C., & Wilson, J. S. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00344 · Cited by 321 · see citing works
The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3
Loetscher, P., Pellegrino, A., Gong, J.-H., Mattioli, I., Loetscher, M., Bardi, G., Baggiolini, M., & Clark‐Lewis, I. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005652200 · Cited by 316 · see citing works
Chen, J. J. W., Yao, P., Yuan, A., Hong, T.-M., Shun, C., Kuo, M., Lee, Y.-C., & Yang, P. (2003) · PubMed · Cited by 309 · see citing works
Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs
Liou, G., Döppler, H. R., Necela, B. M., Krishna, M., Crawford, H. C., Raimondo, M., & Störz, P. (2013) · The Journal of Cell Biology · doi:10.1083/jcb.201301001 · Cited by 296 · see citing works
IL-10 Potentiates Differentiation of Human Induced Regulatory T Cells via STAT3 and Foxo1
Hsu, P. S., Santner‐Nanan, B., Hu, M., Skarratt, K. K., Lee, C. H., Stormon, M., Wong, M., Fuller, S. J., & Nanan, R. K. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402898 · Cited by 288 · see citing works
Lehmann, K. E., Janda, E., Pierreux, C. E., Rytömaa, M., Schulze, A., McMahon, M., Hill, C. S., Beug, H., & Downward, J. (2000) · Genes & Development · doi:10.1101/gad.181700 · Cited by 287 · see citing works
Systemic and local immunosuppression in pancreatic cancer patients.
von Bernstorff, W., Voss, M., Freichel, S., Schmid, A., Vogel, I., Jöhnk, C., Henne‐Bruns, D., Kremer, B., & Kalthoff, H. (2001) · PubMed · Cited by 279 · see citing works
K-ras activation generates an inflammatory response in lung tumors
Ji, H., Houghton, A. M., Mariani, T. J., Perera, S. A., Kim, C. B. Y., Padera, R. F., Tonon, G., McNamara, K. L., Marconcini, L. A. L., Hezel, A. F., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1209237 · Cited by 271 · see citing works
Remark, R., Becker, C., Gomez, J. E., Damotte, D., Dieu‐Nosjean, M., Sautès‐Fridman, C., Fridman, W. H., Powell, C. A., Altorki, N. K., Mérad, M., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201409-1671pp · Cited by 270 · see citing works
Zhang, Y., Yan, W., Collins, M. A., Bednar, F., Rakshit, S., Zetter, B. R., Stanger, B. Z., Chung, I., Rhim, A. D., & di Magliano, M. P. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1558-t · Cited by 261 · see citing works
Schmall, A., Al-tamari, H. M., Herold, S., Kampschulte, M., Weigert, A., Wietelmann, A., Vipotnik, N., Grimminger, F., Seeger, W., Pullamsetti, S. S., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201406-1137oc · Cited by 257 · see citing works
Hasegawa, Y., Takanashi, S., Kanehira, Y., Tsushima, T., Imai, T., & Okumura, K. (2001) · Cancer · doi:10.1002/1097-0142(20010301)91:5 · Cited by 240 · see citing works
Kulkarni, A. B., & Karlsson, S. (1993) · PubMed · Cited by 234 · see citing works
Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis
Marshall, E. A., Ng, K. W., Kung, S. H. Y., Conway, E. M., Martínez, V. D., Halvorsen, E. C., Rowbotham, D. A., Vucic, E. A., Plumb, A. W., Becker‐Santos, D. D., et al. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0551-1 · Cited by 230 · see citing works
Bellone, G., Turletti, A., Artusio, E., Mareschi, K., Carbone, A., Tibaudi, D., Robecchi, A., Emanuelli, G., & Rodeck, U. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65149-8 · Cited by 227 · see citing works
Caetano, M. S., Zhang, H., Cumpian, A. M., Gong, L., Ünver, N., Ostrin, E. J., Daliri, S., Chang, S. H., Ochoa, C. E., Hanash, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2840 · Cited by 227 · see citing works
Cytokines in pancreatic carcinoma
Ebrahimi, B., Tucker, S., Li, D.-H., Abbruzzese, J. L., & Kurzrock, R. (2004) · Cancer · doi:10.1002/cncr.20672 · Cited by 214 · see citing works
Nonhematopoietic tumor cells express functional GM-CSF receptors
Baldwin, G., Gasson, J., Kaufman, S., Quan, S. G., Williams, R., Avalos, B. R., Gazdar, A. F., Golde, D., & DiPersio, J. (1989) · Blood · doi:10.1182/blood.v73.4.1033.1033 · Cited by 209 · see citing works
Bellone, G., Smirne, C., Mauri, F. A., Tonel, E., Carbone, A., Buffolino, A., Dughera, L., Robecchi, A., Pirisi, M., & Emanuelli, G. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0047-0 · Cited by 209 · see citing works
Liou, G., Döppler, H. R., Necela, B. M., Edenfield, B. H., Zhang, L., Dawson, D. W., & Störz, P. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0474 · Cited by 205 · see citing works
Hif1α deletion reveals pro-neoplastic function of B cells in pancreatic neoplasia
Lee, K., Spata, M., Bayne, L., Buza, E., Durham, A., Allman, D., Vonderheide, R., & Simon, M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0822 · Cited by 203 · see citing works
Inflammatory networks and immune surveillance of pancreatic carcinoma
Vonderheide, R. H., & Bayne, L. J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.01.006 · Cited by 200 · see citing works
GM-CSF Mediates Mesenchymal–Epithelial Cross-talk in Pancreatic Cancer
Waghray, M., Yalamanchili, M., Dziubinski, M. L., Zeinali, M., Erkkinen, M., Yang, H., Schradle, K. A., Urs, S., di Magliano, M. P., Welling, T. H., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0947 · Cited by 197 · see citing works
Dickson, R. B., Kasid, A., Huff, K. K., Bates, S. E., Knabbe, C., Bronzert, D. A., Gelmann, E. P., & Lippman, M. E. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.3.837 · Cited by 194 · see citing works
Inhibition of KRAS -Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
Zhu, Z., Aref, A. R., Cohoon, T. J., Barbie, T. U., Imamura, Y., Yang, S., Moody, S. E., Shen, R. R., Schinzel, A. C., Thai, T. C., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0646 · Cited by 193 · see citing works
Chang, C.-H., Hsiao, C.-F., Yeh, Y.-M., Chang, G., Tsai, Y.-H., Chen, Y.-M., Huang, M.-S., Chen, H.-L., Li, Y.-J., Yang, P.-C., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27892 · Cited by 187 · see citing works
Kusmartsev, S. A., & Gabrilovich, D. I. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9002-6 · Cited by 183 · see citing works
Overexpression of CXCL5 Is Associated With Poor Survival in Patients With Pancreatic Cancer
Li, A., King, J. C., Moro, A., Sugi, M. D., Dawson, D. W., Kaplan, J., Li, G., Lu, X., Strieter, R. M., Burdick, M. D., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.058 · Cited by 177 · see citing works
Andoh, A., Takaya, H., Saotome, T., Shimada, M., Hata, K., Araki, Y., Nakamura, F., Shintani, Y., Fujiyama, Y., & Bamba, T. (2000) · Gastroenterology · doi:10.1053/gast.2000.8538 · Cited by 165 · see citing works
Moo‐Young, T. A., Larson, J. W., Belt, B. A., Tan, M. C. B., Hawkins, W. G., Eberlein, T. J., Goedegebuure, P. S., & Linehan, D. C. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318189f13c · Cited by 165 · see citing works
TLR9 ligation in pancreatic stellate cells promotes tumorigenesis
Zambirinis, C. P., Levie, E., Nguy, S., Avanzi, A., Barilla, R., Xu, Y., Seifert, L., Daley, D., Greco, S. H., Deutsch, M., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20142162 · Cited by 164 · see citing works
Wislez, M., Fujimoto, N., Izzo, J. G., Hanna, A. E., CODY, D. D., Langley, R. R., Tang, H., Burdick, M. D., Sato, M., Minna, J. D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3842 · Cited by 164 · see citing works
Tang, D., Yuan, Z., Xue, X., Lu, Z., Zhang, Y., Wang, H., Chen, M., An, Y., Wei, J., Zhu, Y., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26290 · Cited by 163 · see citing works
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer
Herter-Sprie, G. S., Koyama, S., Korideck, H., Hai, J., Deng, J., Li, Y. Y., Buczkowski, K. A., Grant, A. K., Ullas, S., Rhee, K., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87415 · Cited by 161 · see citing works
Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer
Cullis, J. E., Siolas, D., Avanzi, A., Barui, S., Maitra, A., & Bar‐Sagi, D. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0125 · Cited by 161 · see citing works
Self-citationClark, C. E., Beatty, G. L., & Vonderheide, R. H. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.09.037 · Cited by 157 · see citing works
Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells
Zdanov, S., Mandapathil, M., Eid, R. A., Adamson-Fadeyi, S., Wilson, W., Qian, J., Carnie, A., Tarasova, N. I., Mkrtichyan, M., Berzofsky, J. A., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0241 · Cited by 157 · see citing works
Increased interleukin-10 serum levels in patients with solid tumours
Fortis, C., Foppoli, M., Gianotti, L. V., Galli, L., Citterio, G., Consogno, G., Gentilini, O., & Braga, M. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04213-9 · Cited by 154 · see citing works
Dai, F., Liu, L.-X., Che, G., Yu, N., Pu, Q., Zhang, S., Ma, J., Ma, L., & You, Z. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-220 · Cited by 151 · see citing works
Elevated serum interleukin-6 levels in patients with pancreatic cancer.
Okada, S., Okusaka, T., Ishii, H., Kyogoku, A., Yoshimori, M., Kajimura, N., Yamaguchi, K., & Kakizoe, T. (1998) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/28.1.12 · Cited by 150 · see citing works
Nemunaitis, J., Nemunaitis, M., Senzer, N., Snitz, P., Bedell, C., Kumar, P., Pappen, B., Maples, P. B., Shawler, D., & Fakhrai, H. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.15 · Cited by 147 · see citing works
Lung Cancer Subtypes Generate Unique Immune Responses
Busch, S., Hanke, M. L., Kargl, J., Metz, H. E., MacPherson, D. P., & Houghton, A. M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600576 · Cited by 147 · see citing works
Takeuchi, S., Baghdadi, M., Tsuchikawa, T., Wada, H., Nakamura, T., Abe, H., Nakanishi, S., Usui, Y., Higuchi, K., Takahashi, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2921 · Cited by 138 · see citing works
Kenkel, J. A., Tseng, W. W., Davidson, M. G., Tolentino, L. L., Choi, O., Bhattacharya, N., Seeley, E. S., Winer, D. A., Reticker-Flynn, N. E., & Engleman, E. G. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2212 · Cited by 133 · see citing works
Lunardi, S., Jamieson, N. B., Lim, S. Y., Griffiths, K., Carvalho‐Gaspar, M., Al‐Assar, O., Yameen, S., Carter, R. C., McKay, C. J., Spoletini, G., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2519 · Cited by 131 · see citing works
Lüttges, J., Reinecke-Lüthge, A., Möllmann, B., Menke, M. A. O. H., Clemens, A., Klimpfinger, M., Sipos, B., & Klöppel, G. (1999) · Virchows Archiv · doi:10.1007/s004280050428 · Cited by 127 · see citing works
Markowitz, J., Brooks, T., Duggan, M. C., Paul, B. K., Pan, X. J., Wei, L., Abrams, Z. B., Luedke, E. A., Lesinski, G. B., Mundy-Bosse, B. L., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1618-8 · Cited by 126 · see citing works
Redente, E. F., Higgins, D. M., Dwyer‐Nield, L. D., Orme, I. M., Juarrero, M. G., & Malkinson, A. M. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0609378 · Cited by 123 · see citing works
Mathew, E., Brannon, A., Vecchio, A. D., Garcia, P. E., Penny, M. K., Kane, K. T., Vinta, A., Buckanovich, R. J., & di Magliano, M. P. (2016) · Neoplasia · doi:10.1016/j.neo.2016.01.005 · Cited by 121 · see citing works
Feurino, L. W., Zhang, Y., Bharadwaj, U., Zhang, R., Li, F., Fisher, W. E., Brunicardi, F. C., Chen, C., Yao, Q. C., & Li, M. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.7.4328 · Cited by 115 · see citing works
Curcumin inhibits COPD-like airway inflammation and lung cancer progression in mice
Moghaddam, S. J., Barta, P., Mirabolfathinejad, S. G., Ammar-Aouchiche, Z., Garza, N., Vo, T. T., Newman, R. A., Aggarwal, B. B., Evans, C. M., Tuvim, M. J., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp229 · Cited by 115 · see citing works
K-ras mutation in focal proliferative lesions of human pancreas.
Terhune, P. G., Phifer, D. M., Tosteson, T. D., & Longnecker, D. S. (1998) · PubMed · Cited by 114 · see citing works
Interleukin-6: a villain in the drama of pancreatic cancer development and progression
Holmer, R., Goumas, F. A., Waetzig, G. H., Rose‐John, S., & Kalthoff, H. (2014) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(14)60259-9 · Cited by 108 · see citing works
Targeting cytotoxic T lymphocytes for cancer immunotherapy
Maher, J. F., & Davies, E. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602022 · Cited by 107 · see citing works
Mroczko, B., Groblewska, M., Gryko, M., Kędra, B., & Szmitkowski, M. (2010) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.20395 · Cited by 103 · see citing works
CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice
Zhang, Y., Yan, W., Mathew, E., Bednar, F., Wan, S., Collins, M. A., Evans, R. A., Welling, T. H., Vonderheide, R. H., & di Magliano, M. P. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0016-t · Cited by 102 · see citing works
Wigmore, S. J., Fearon, K. C. H., Sangster, K., Maingay, J. P., Garden, O. J., & Ross, J. (2002) · International Journal of Oncology · doi:10.3892/ijo.21.4.881 · Cited by 101 · see citing works
Impact of tumour associated macrophages in pancreatic cancer
Mielgo, A., & Schmid, M. C. (2013) · BMB Reports · doi:10.5483/bmbrep.2013.46.3.036 · Cited by 101 · see citing works
Mutant KRAS promotes malignant pleural effusion formation
Agalioti, T., Giannou, A. D., Krontira, A. C., Kanellakis, N. I., Kati, D., Vreka, M., Pepe, M. A. A., Σπέλλα, Μ., Lilis, I., Zazara, D. E., et al. (2017) · Nature Communications · doi:10.1038/ncomms15205 · Cited by 100 · see citing works
Immunotherapy: The Path to Win the War on Cancer?
Topalian, S. L., Wolchok, J. D., Chan, T. A.-T., Mellman, I., Palucka, K., Banchereau, J., Rosenberg, S. A., & Wittrup, K. D. (2015) · Cell · doi:10.1016/j.cell.2015.03.045 · Cited by 99 · see citing works
Interleukin-6 prevents the initiation but enhances the progression of lung cancer
Qu, Z.-X., Sun, F., Zhou, J.-J., Li, L., Shapiro, S., & Xiao, G. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3042 · Cited by 99 · see citing works
Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer
Hatanaka, H., Abe, Y., Kamiya, T., Morino, F., Nagata, J., Tokunaga, T., Oshika, Y., Suemizu, H., Kijima, H., Tsuchida, T., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008375208574 · Cited by 99 · see citing works
Means, A. L., Ray, K. C., Singh, A. B., Washington, M. K., Whitehead, R. H., Harris, R. C., Wright, C. V. E., Coffey, R. J., & Leach, S. D. (2003) · Gastroenterology · doi:10.1053/gast.2003.50150 · Cited by 97 · see citing works
Talar‐Wojnarowska, R., Gąsiorowska, A., Smolarz, B., Romanowicz‐Makowska, H., Kulig, A., & Malecka-Panas, E. I. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0390-z · Cited by 95 · see citing works
A ras- Mutated Peptide Targeted by CTL Infiltrating a Human Melanoma Lesion
Linard, B., Bezieau, S., Benlalam, H., Labarrière, N., Guilloux, Y., Diez, E., & Jotereau, F. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4802 · Cited by 88 · see citing works
The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration
Watt, J., & Kocher, H. M. (2013) · OncoImmunology · doi:10.4161/onci.26788 · Cited by 87 · see citing works
Tewari, N., Zaitoun, A. M., Arora, A., Madhusudan, S., Ilyas, M., & Lobo, D. N. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-436 · Cited by 83 · see citing works
A Central Role for Foxp3+ Regulatory T Cells in K-Ras-Driven Lung Tumorigenesis
Granville, C. A., Memmott, R. M., Balogh, A., Mariotti, J., Kawabata, S., Han, W., LoPiccolo, J., Foley, J., Liewehr, D. J., Steinberg, S. M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005061 · Cited by 79 · see citing works
Tsubaki, M., Yamazoe, Y., Yanae, M., Satou, T., Itoh, T., Kaneko, J., Kidera, Y., Moriyama, K., & Nishida, S. (2011) · Cytokine · doi:10.1016/j.cyto.2011.01.005 · Cited by 77 · see citing works
Pathological and Molecular Evaluation of Pancreatic Neoplasms
Rishi, A., Goggins, M., Wood, L. D., & Hruban, R. H. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.12.004 · Cited by 77 · see citing works
Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer
Yamaji, H., Iizasa, T., Koh, E., Suzuki, M., Otsuji, M., Chang, H., Motohashi, S., Yokoi, S., Hiroshima, K., Tagawa, M., et al. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0533-9 · Cited by 76 · see citing works
Pancreatic cancer-associated stellate cells
Mace, T. A., Bloomston, M., & Lesinski, G. B. (2013) · OncoImmunology · doi:10.4161/onci.24891 · Cited by 68 · see citing works
Fossum, B., Olsen, A. C., Thorsby, E., & Gaudernack, G. (1995) · Cancer Immunology Immunotherapy · doi:10.1007/bf01517348 · Cited by 61 · see citing works
Tang, D., Gao, J., Wang, S., Yuan, Z., Ye, N., Chong, Y., Xu, C., Jiang, X., Li, B., Yin, W., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3233-5 · Cited by 61 · see citing works
Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer
Zhou, J.-B., Min, Z., Zhang, D., Wang, W., Marincola, F., & Wang, X.-D. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0304-0 · Cited by 59 · see citing works
Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
Kubuschok, B., Neumann, F., Breit, R., Sester, M., Schormann, C., Wagner, C., Sester, U., Hartmann, F., Wagner, M., REMBERGER, K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1672 · Cited by 58 · see citing works
Taş, F., Duranyıldız, D., Oğuz, H., Çamlıca, H., Yasasever, V., & Topuz, E. (2006) · Cancer Investigation · doi:10.1080/07357900600814771 · Cited by 55 · see citing works
Pauken, K. E., Nelson, C. E., Martinov, T., Spanier, J. A., Heffernan, J. R., Sahli, N. L., Quarnstrom, C. F., Osum, K. C., Schenkel, J. M., Jenkins, M. K., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402262 · Cited by 52 · see citing works
Kordes, C., Brookmann, S., H�ussinger, D., & Klonowski-Stumpe, H. (2005) · Pancreas · doi:10.1097/01.mpa.0000168222.05591.a0 · Cited by 52 · see citing works
Interleukin-6 is increased in breath condensate of patients
Carpagnano, G. E., Resta, O., Foschino-Barbaro, M. P., Gramiccioni, E., & Carpagnano, F. (2002) · The International Journal of Biological Markers · doi:10.5301/jbm.2008.172 · Cited by 52 · see citing works
Enhanced ENA-78 and IL-8 Expression in Patients with Malignant Pancreatic Diseases
Frick, V. O., Rubie, C., Wagner, M., Graeber, S. M., Grimm, H., Kopp, B., Rau, B., & Schilling, M. K. (2008) · Pancreatology · doi:10.1159/000151776 · Cited by 50 · see citing works
Ortegel, J. W., Staren, E. D., Faber, L. P., Warren, W. H., & Braun, D. P. (2002) · Lung Cancer · doi:10.1016/s0169-5002(01)00472-x · Cited by 47 · see citing works
Toomey, D., Smyth, G. P., Condron, C. M., Kelly, J. J., Byrne, A., Kay, E. W., Conroy, R. M., Broe, P. J., & Bouchier‐Hayes, D. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.10836 · Cited by 44 · see citing works
Delitto, D., Black, B. S., Sorenson, H. L., Knowlton, A. E., Thomas, R. M., Sarosi, G. A., Moldawer, L. L., Behrns, K. E., Liu, C., George, T. J., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1820-x · Cited by 44 · see citing works
Cancer Immunotherapy: Whence and Whither
Stambrook, P. J., Maher, J. F., & Farzaneh, F. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0427 · Cited by 43 · see citing works
T-Cell Transfer Therapy Targeting Mutant KRAS
Maoz, A., Rennert, G., & Gruber, S. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1616637 · Cited by 43 · see citing works
CXCR2 signaling regulates KRAS(G12D)-induced autocrine growth of pancreatic cancer
Purohit, A., Varney, M. L., Rachagani, S., Ouellette, M. M., Batra, S. K., & Singh, R. K. (2016) · Oncotarget · doi:10.18632/oncotarget.6906 · Cited by 42 · see citing works
Constitutive activation of NF-κB in Ki-ras-transformed prostate epithelial cells
Kim, B.-Y., Gaynor, R. B., Song, K. W., Dritschilo, A., & Jung, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205547 · Cited by 41 · see citing works
Wenger, F. A., Jacobi, C. A., Zieren, J., Döcke, W. ‐., Volk, H., & Müller, J. M. (1999) · Langenbeck s Archives of Surgery · doi:10.1007/s004230050233 · Cited by 37 · see citing works
Increased B Cell-Activating Factor Promotes Tumor Invasion and Metastasis in Human Pancreatic Cancer
Koizumi, M., Hiasa, Y., Kumagi, T., Yamanishi, H., Azemoto, N., Kobata, T., Matsuura, B., Abe, M., & Onji, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071367 · Cited by 37 · see citing works
ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis
O’Hayer, K., Brady, D. C., & Counter, C. M. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp198 · Cited by 37 · see citing works
Interleukin-6 is Increased in Breath Condensate of Patients with Non-Small Cell Lung Cancer
Carpagnano, G. E., Resta, O., Foschino-Barbaro, M. P., Gramiccioni, E., & Carpagnano, F. (2002) · The International Journal of Biological Markers · doi:10.1177/172460080201700211 · Cited by 33 · see citing works
Tateishi, M., Ishida, T., Mitsudomi, T., & Sugimachi, K. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.26 · Cited by 31 · see citing works
PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction
Principe, D. R., DeCant, B. T., Diaz, A. M., Mangan, R. J., Hwang, R. F., Lowy, A. M., Shetuni, B., Sreekumar, B. K. N., Chung, C., Bentrem, D. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8587 · Cited by 30 · see citing works
Inflammatory macrophages in pancreatic acinar cell metaplasia and initiation of pancreatic cancer
Liou, G., & Störz, P. (2015) · Oncoscience · doi:10.18632/oncoscience.151 · Cited by 29 · see citing works
Sharma, G., Whang, E. E., Ruan, D. T., & Ito, H. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4711-0 · Cited by 28 · see citing works
Immunotherapy for Non-Small Cell Lung Cancer
Yoon, S. H. (2014) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2014.77.3.111 · Cited by 27 · see citing works
Vasiliades, G., Kopanakis, N. D., Vasiloglou, M., Zografos, G., Margaris, H., Masselou, K., Kokosi, E., & Liakakos, T. (2012) · The International Journal of Biological Markers · doi:10.5301/jbm.2012.9348 · Cited by 23 · see citing works
Decreased IL‐27 Negatively Correlated with Th17 Cells in Non‐Small‐Cell Lung Cancer Patients
Duan, M., Ning, Z., Fu, Z.-J., Zhang, J., Liu, G., Wei, Q., & Zheng, X. (2015) · Mediators of Inflammation · doi:10.1155/2015/802939 · Cited by 22 · see citing works
T-Cell Transfer Therapy Targeting Mutant KRAS.
Rosenberg, S. A., Tran, E., & Robbins, P. F. (2017) · PubMed · Cited by 16 · see citing works
Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma
Francini, G., Petrioli, R., Gonnelli, S., Correale, P., Pozzessere, D., Marsili, S., Montagnani, A., Lucani, B., Rossi, S., Monaco, R. D., et al. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6 · Cited by 15 · see citing works
Trojan, A., Urosevic, M., Hummerjohann, J., Giger, R., Schanz, U., & Stahel, R. A. (2003) · Journal of Immunotherapy · doi:10.1097/00002371-200301000-00005 · Cited by 14 · see citing works
Interactions of pancreatic cancer and stellate cells are mediated by FGFR1-III isoform expression.
Tian, X., Chen, G., Zhou, S., Henne‐Bruns, D., Bachem, M. G., & Kornmann, M. (2012) · PubMed · doi:10.5754/hge10366 · Cited by 13 · see citing works
Huang, F., Wang, X., Geng, Y., & Li, M.-X. (2005) · PubMed · Cited by 4 · see citing works
Petrovic, M. D., Ilić, N., Lazić, Z., Čekerevac, I., Novković, L., Kostić, G., & Ćupurdija, V. (2011) · European Respiratory Journal · doi:10.1183/13993003/erj.38.suppl_55.p2798 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127 · see citing works
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Braicu, C., Buse, M., Busuioc, C. I., Drulă, R., Gulei, D., Ráduly, L., Alexandru Vasile, R. U. S. U., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 940 · see citing works
Genomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448 · see citing works
Therapeutic strategies to target RAS-mutant cancers
Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420 · see citing works
Immune modulatory effects of oncogenic KRAS in cancer
Hamarsheh, S., Groß, O., Brummer, T., & Zeiser, R. (2020) · Nature Communications · doi:10.1038/s41467-020-19288-6 · Cited by 387 · see citing works
Tumor Cell–Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer
Das, S., Shapiro, B., Vucic, E., Vogt, S., & Bar‐Sagi, D. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2080 · Cited by 368 · see citing works
Self-citationOncogenic driver mutations in non-small cell lung cancer: Past, present and future
Chevallier, M., Borgeaud, M., Addeo, A., & Friedlaender, A. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i4.217 · Cited by 321 · see citing works
KRAS drives immune evasion in a genetic model of pancreatic cancer
Ischenko, I., D’Amico, S., Rao, M., Li, J., Hayman, M. J., Powers, S., Petrenko, O., & Reich, N. C. (2021) · Nature Communications · doi:10.1038/s41467-021-21736-w · Cited by 184 · see citing works
Mugarza, E., van Maldegem, F., Boumelha, J., Moore, C., Rana, S., Llorian, M., East, P., Ambler, R., Anastasiou, P., Romero-Clavijo, P., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm8780 · Cited by 144 · see citing works
Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer
Kleczko, E. K., Kwak, J., Schenk, E. L., & Nemenoff, R. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00954 · Cited by 121 · see citing works
Tokumaru, Y., Oshi, M., Katsuta, E., Yan, L., Satyananda, V., Matsuhashi, N., Futamura, M., Akao, Y., Yoshida, K., & Takabe, K. (2020) · PubMed Central · Cited by 105 · see citing works
Combinatorial strategies to target RAS-driven cancers
Perurena, N., Situ, L., & Cichowski, K. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00679-6 · Cited by 104 · see citing works
Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics
Chen, H., Smaill, J. B., Liu, T., Ding, K., & Lu, X. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01312 · Cited by 100 · see citing works
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 98 · see citing works
KRAS G12C–Mutant Non–Small Cell Lung Cancer
Veluswamy, R., Mack, P. C., Houldsworth, J., Elkhouly, E., & Hirsch, F. R. (2021) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.02.002 · Cited by 96 · see citing works
Macropinocytosis as a cell entry route for peptide-functionalized and bystander nanoparticles
Li, Y., & Pang, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.049 · Cited by 84 · see citing works
KRAS G12C Mutations in NSCLC: From Target to Resistance
Addeo, A., Banna, G. L., & Friedlaender, A. (2021) · Cancers · doi:10.3390/cancers13112541 · Cited by 84 · see citing works
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 80 · see citing works
A bright future for KRAS inhibitors
Bar-Sagi, D., Knelson, E. H., & Sequist, L. V. (2020) · Nature Cancer · doi:10.1038/s43018-019-0016-8 · Cited by 74 · see citing works
Self-citationDrugging the Undruggable: Advances on RAS Targeting in Cancer
Molina‐Arcas, M., Samani, A., & Downward, J. (2021) · Genes · doi:10.3390/genes12060899 · Cited by 73 · see citing works
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
Merz, V., Gaule, M., Zecchetto, C., Cavaliere, A., Casalino, S., Pesoni, C., Contarelli, S., Sabbadini, F., Bertolini, M., Mangiameli, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638360 · Cited by 71 · see citing works
KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications
Pereira, F. D. S., Ferreira, A. I., Reis, C. A., Sousa, M. J., Oliveira, M. J., & Preto, A. (2022) · Cells · doi:10.3390/cells11030398 · Cited by 74 · see citing works
Santarpia, M., Ciappina, G., Spagnolo, C. C., Squeri, A., Passalacqua, M. I., Aguilar, A., Gonzalez-Cao, M., Giovannetti, E., Silvestris, N., & Rosell, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-639 · Cited by 65 · see citing works
Improving outcomes of patients with pancreatic cancer
Dreyer, S. B., Beer, P. A., Hingorani, S. R., & Biankin, A. V. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01019-9 · Cited by 66 · see citing works
Overcoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61 · see citing works
Zhuang, H., Zhou, Z., Ma, Z., Li, Z., Liu, C., Huang, S., Zhang, C., & Hou, B. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15990 · Cited by 60 · see citing works
Cancer vaccines: Targeting KRAS-driven cancers
Zhang, Y., Ma, J., Zhang, H.-X., Jiang, Y., & Luo, W. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1733420 · Cited by 58 · see citing works
Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity
Mansouri, S., Heylmann, D., Stiewe, T., Kracht, M., & Savai, R. (2022) · eLife · doi:10.7554/elife.79895 · Cited by 45 · see citing works
Prognostic values and immune suppression of the S100A family in pancreatic cancer
Zhuang, H., Chen, X., Dong, F., Zhang, Z., Zhou, Z., Ma, Z., Huang, S., Chen, B., Zhang, C., & Hou, B. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16343 · Cited by 45 · see citing works
Uniyal, P., Kashyap, V. K., Behl, T., Parashar, D., & Rawat, R. (2025) · Cancers · doi:10.3390/cancers17050785 · Cited by 45 · see citing works
Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer
Janssen, J. B. E., Medema, J. P., Gootjes, E. C., Tauriello, D. V. F., & Verheul, H. M. W. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102433 · Cited by 41 · see citing works
Mutant KRAS at the heart of tumor immune evasion
van Maldegem, F., & Downward, J. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.013 · Cited by 32 · see citing works
Zhuang, H., Zhang, C., & Hou, B. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02365-z · Cited by 31 · see citing works
Zhao, L.-P., Hu, J.-H., Hu, D., Wang, H., Huang, C.-G., Luo, R., Huang, X., Huang, X., Xie, T., & Lou, J.-S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112949 · Cited by 32 · see citing works
Wang, F., Yang, M., Luo, W., & Zhou, Q. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.10.002 · Cited by 31 · see citing works
Biology, pathology, and therapeutic targeting of RAS
Rhett, J. M., Khan, I., & O’Bryan, J. P. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.05.002 · Cited by 28 · see citing works
A Spontaneous Aggressive ERα+ Mammary Tumor Model Is Driven by Kras Activation
Campbell, K. M., O’Leary, K. A., Rugowski, D. E., Mulligan, W. A., Barnell, E. K., Skidmore, Z. L., Krysiak, K., Griffith, M., Schuler, L. A., & Griffith, O. L. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.098 · Cited by 28 · see citing works
Zhuang, H., Chen, X., Wang, Y., Huang, S., Chen, B., Zhang, C., & Hou, B. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03019-x · Cited by 26 · see citing works
Zhuang, H., Zhou, Z., Zhang, Z., Chen, X., Ma, Z., Huang, S., Gong, Y., Zhang, C., & Hou, B. (2020) · Aging · doi:10.18632/aging.202255 · Cited by 25 · see citing works
PDAC as an immune evasive disease: can 3D model systems aid to tackle this clinical problem?
Narayanan, S., Vicent, S., & Ponz-Sarvisé, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.787249 · Cited by 24 · see citing works
Tian, L., Li, H., Cui, H., Tang, C., Zhao, P., Wang, X., & Cheng, Y. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08101-1 · Cited by 26 · see citing works
I, A. R., Shiu, K., & Khan, K. H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1142838 · Cited by 21 · see citing works
Yuan, K., Feng, Y., Wang, H., Zhao, L., Wang, W. T., Wang, T., Feng, Y., Huang, G., & Xu, A. (2020) · PeerJ · doi:10.7717/peerj.8654 · Cited by 21 · see citing works
KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
García-Robledo, J. E., Rosell, R., Ruíz-Patiño, A., Sotelo, C., Arrieta, O. G., Zatarain-Barrón, L., Ordóñez‐Reyes, C., Jaller, E., Rojas, L., Russo, A., et al. (2022) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666211066064 · Cited by 20 · see citing works
Ye, Y., Zhao, Q., Wu, Y., Wang, G., Huang, Y., Sun, W., & Zhang, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.989719 · Cited by 20 · see citing works
Wang, M., Zhu, L., Yang, X., Li, J., Liu, Y., & Ying, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1132158 · Cited by 20 · see citing works
Hlophe, Y. N., & Joubert, A. M. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17571 · Cited by 20 · see citing works
Sun, M., Xie, M., Zhang, T., Wang, Y., Huang, W., & Xia, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.739768 · Cited by 18 · see citing works
KRAS mutations are negatively correlated with immunity in colon cancer
Fu, X., Wang, X., Duanmu, J., Li, T., & Jiang, Q. (2020) · Aging · doi:10.18632/aging.202182 · Cited by 20 · see citing works
wang, F., Gao, X., Wang, P., He, H., Chen, P., Liu, Z., Chen, Y., Zhou, H., Chen, W., Yi, X., et al. (2021) · Frontiers in Immunology · doi:10.2139/ssrn.3970711 · Cited by 17 · see citing works
Cao, P., Liu, L., Li, Z.-H., Cao, F., & Liu, F. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.853471 · Cited by 15 · see citing works
Li, Z., Zhuang, H., Chen, X., Zhang, Y., Ma, Z., Wang, S., Yan, Q., Zhou, Z., Huang, S., Zhang, C., et al. (2022) · Journal of Oncology · doi:10.1155/2022/4269733 · Cited by 15 · see citing works
Malik, P., Rani, R., Solanki, R., Patel, V. H., & Mukherjee, T. K. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00171 · Cited by 13 · see citing works
Spagnuolo, A., Maione, P., & Gridelli, C. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-948 · Cited by 14 · see citing works
Exploring lung cancer microenvironment: pathways and nanoparticle-based therapies
Arandhara, A., Bhuyan, P., & Das, B. K. (2025) · Discover Oncology · doi:10.1007/s12672-025-01902-y · Cited by 12 · see citing works
Schuler, L. A., & Murdoch, F. E. (2021) · Cancers · doi:10.3390/cancers13153725 · Cited by 12 · see citing works
Jiang, Y., Liu, Y., Huang, H., Zhao, T., Zhao, Z., & Gao, Y. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03926-9 · Cited by 11 · see citing works
Principe, D. R., Pasquinelli, M. M., Nguyen, R. H.-T., Munshi, H. G., Hulbert, A., Aissa, A. F., & Weinberg, F. D. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0153 · Cited by 11 · see citing works
Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
Fu, S., Ma, J., Cai, C., Tan, J., Deng, X., Shen, H., Zeng, S., Chen, Y., & Han, Y. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03444-1 · Cited by 11 · see citing works
Carvalho, P. D., Mendonça, S., Martins, F., Oliveira, M. J., & Velho, S. (2022) · Cells · doi:10.3390/cells11162490 · Cited by 10 · see citing works
AZD4625 is a Potent and Selective Inhibitor of KRASG12C
Chakraborty, A., Hanson, L. L., Robinson, D. M., Lewis, H. J., Bickerton, S., Davies, M., Polański, R., Whiteley, R., Koers, A., Atkinson, J. M., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0241 · Cited by 9 · see citing works
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation
Jeong, S. Y., Hong, J. Y., Park, J. O., Park, Y. S., Lim, H. Y., Jang, J. Y., Jeon, Y., & Kim, S. T. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231170484 · Cited by 8 · see citing works
Fonseca-Montaño, M. A., Cisneros-Villanueva, M., Coales, I., & Hidalgo‐Miranda, A. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1034569 · Cited by 8 · see citing works
He, X., Xu, Z., Ren, R., Wan, P., Zhang, Y., Wang, L., & Han, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23659 · Cited by 7 · see citing works
Single Cell Inference of Cancer Drug Response Using Pathway‐Based Transformer Network
Yao, Y., Xu, Y., Zhang, Y., Gui, Y., Bai, Q., Zhu, Z., Peng, H., Zhou, Y., Chen, Z. J., Sun, J., et al. (2025) · Small Methods · doi:10.1002/smtd.202400991 · Cited by 7 · see citing works
Kato, Y., Shirai, R., Ohbuchi, K., Oizumi, H., Yamamoto, M., Miyata, W., Iguchi, T., Mimaki, Y., Miyamoto, Y., & Yamauchi, J. (2023) · Neurology International · doi:10.3390/neurolint15010025 · Cited by 7 · see citing works
Yang, X., Feng, S., Zhang, Q., Li, W., Li, S., Zhi, M., Lan, P., & Cheng, S. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06864-x · Cited by 6 · see citing works
Chang, H., Chen, H., Ma, T., Ma, K., Li, Y., Suo, L., Liang, X., Jia, K., Ma, J., Li, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-60780-6 · Cited by 6 · see citing works
Huang, R., Gong, X., Du, J., Xu, G., Qian, J., Liao, G., Lin, Y., Pan, M., Zheng, B., Yuan, W., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1704347 · Cited by 6 · see citing works
Fan, G. (2024) · American Journal of Cancer Research · doi:10.62347/nuxc8231 · Cited by 5 · see citing works
Podaza, E., Capuano, J. A., Assaad, M. A., Kuo, H., Markowitz, G. J., Irizarry, A., Ravichandran, H., Ackermann, S. E., Kane, T., Manohar, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.05.546622 · Cited by 5 · see citing works
Homan, E. J., & Bremel, R. D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155679 · Cited by 4 · see citing works
Zhang, T., Han, H., Zhang, T., Zhang, Y., Ma, L., Yang, Z. R., & Zhao, Y. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189459 · Cited by 3 · see citing works
Lv, Y., Zhao, Z., Di, W., Liu, L., Chen, Y., Wei, S., Ji, Y., & Zhong, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105150 · Cited by 3 · see citing works
Systematic and precise interventions for KRAS-mutant cancers
Liang, J., Wu, J., Zhang, Y., Wang, H., Zheng, Y., & He, Q. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00763-7 · Cited by 3 · see citing works
Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors
Tripathi, P., Kumari, R., & Pathak, R. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2023.11.004 · Cited by 3 · see citing works
Construction of an immune-related signature with prognostic value for colon cancer
Lv, Y., Wang, X., Ren, Y., Fu, X., Li, T., & Jiang, Q. (2021) · PeerJ · doi:10.7717/peerj.10812 · Cited by 3 · see citing works
Zhuang, H., Tang, C., Han, L., Zhang, Z., Chen, X., Wang, W., Wang, Q., Tan, W., Yang, L., Xie, Z., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00921-1 · Cited by 2 · see citing works
Sahu, P., Mitra, A., & Ganguly, A. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.01.005 · Cited by 2 · see citing works
Insights into direct KRAS inhibition strategies for cancer treatment
Li, T., Gu, C., Zhou, C., Mao, C., Yang, K., Xu, J., Lu, T., & Chen, J. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2424149 · Cited by 3 · see citing works
Podaza, E., Capuano, J. A., Kuo, H., Assaad, M. A., Markowitz, G. J., Revuelta, M. V., Nguyen, J., Irizarry, A., Ravichandran, H., Ackermann, S., et al. (2026) · Cell Reports Methods · doi:10.1016/j.crmeth.2026.101339 · Cited by 1 · see citing works
Kim, B., & Lee, J. H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135682 · Cited by 1 · see citing works
Cheng, Y., Hu, J., Gao, X., Yan, B., Xu, Z., Liu, Y., Zhu, J., Liu, Z., Wang, Y., Wang, J., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1728 · Cited by 1 · see citing works
Imaging mass cytometry in preclinical studies of lung cancer
van Maldegem, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822213-3.00004-8 · Cited by 1 · see citing works
Ramachandran, V., Koyou, H. L., Raajasekar, S., Mohamed, M. H., Mat, L. N. I., Swaminathan, V., Salleh, M. N., Prastiyanto, M. E., & Ahmad, N. A. B. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1933939
BindingDB (2022) · UC San Diego · doi:10.7270/q2t1578s
- Authors
- Cullis, J., Das, S., & Bar-Sagi, D.
- Affiliations
- New York University (US)
- ORCID
- Das, Shipra
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-12-11
- Volume
- 8
- Issue
- 9
- Pages
- a031849
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC6120695
- OpenAlex
- W2772685043
- Cited by
- 85
- References
- 159
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 11 · 2023: 11 · 2022: 14 · 2021: 14 · 2020: 15 · 2019: 4 · 2018: 1
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research (SU2C/AACR DT-14-14, 13-90-25-VOND)
- Pancreatic Cancer Action Network
- Lustgarten Foundation (SU2C-AACR-DT14-14)
- Entertainment Industry Foundation
- National Institutes of Health
- Stand Up To Cancer (SU2C-AACR-DT14-14)
- National Cancer Institute (T32CA009161, R35CA210263)
- National Institute of Allergy and Infectious Diseases (T32AI100853)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- KRAS, antitumor immunity, oncogenic KRAS, tumor microenvironment, NF-κB signaling, pro-inflammatory signaling, cancer-associated fibroblasts, tumor immunosuppression, cancer immunotherapy
- MeSH terms
- Humans, Immunotherapy, Mutation, Neoplasms, Proto-Oncogene Proteins p21(ras), Gene Regulatory Networks, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
